Who are Revanex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nexium, Aciphex, Cedilanid D, Digicor, Acylanid, Uabaina.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/revaprazan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Revanex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Revanex (REVAPRAZAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: revaprazan. Area: Gastroenterology.

marketed revaprazan Potassium-transporting ATPase Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Revanex (REVAPRAZAN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Revanex TARGET	REVAPRAZAN		marketed	revaprazan	Potassium-transporting ATPase
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Aciphex	rabeprazole	Waylis	marketed	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Cedilanid D	DESLANOSIDE	Novartis	marketed	deslanoside	Sodium/potassium-transporting ATPase	1982-01-01
Digicor	DIGITOXIN	Eli Lilly	marketed	digitoxin	Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1	1982-01-01
Acylanid	ACETYLDIGITOXIN	Novartis	marketed	acetyldigitoxin	Sodium/potassium-transporting ATPase	1975-01-01
Uabaina	ouabain		marketed	ouabain	Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (revaprazan class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Revanex — Competitive Intelligence Brief. https://druglandscape.com/ci/revaprazan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing